These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 19414350

  • 1. Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells.
    Tanaka T, Kawashima H, Ohnishi K, Matsumura K, Yoshimura R, Matsuyama M, Kuratsukuri K, Nakatani T.
    Anticancer Res; 2009 Apr; 29(4):1089-94. PubMed ID: 19414350
    [Abstract] [Full Text] [Related]

  • 2. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
    Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW.
    J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
    Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E.
    Prostate Cancer Prostatic Dis; 2005 Jul; 8(3):253-9. PubMed ID: 15999121
    [Abstract] [Full Text] [Related]

  • 5. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
    Kellinsalmi M, Mönkkönen H, Mönkkönen J, Leskelä HV, Parikka V, Hämäläinen M, Lehenkari P.
    Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):382-91. PubMed ID: 16364054
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bisphosphonate treatment inhibits the growth of prostate cancer cells.
    Lee MV, Fong EM, Singer FR, Guenette RS.
    Cancer Res; 2001 Mar 15; 61(6):2602-8. PubMed ID: 11289137
    [Abstract] [Full Text] [Related]

  • 10. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H, Sohara Y, Moats RA, Nelson MD, Groshen SG, Ye W, Reynolds CP, DeClerck YA.
    Cancer Res; 2007 Oct 01; 67(19):9346-55. PubMed ID: 17909043
    [Abstract] [Full Text] [Related]

  • 11. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
    Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH.
    Calcif Tissue Int; 2008 Mar 01; 82(3):191-201. PubMed ID: 18259679
    [Abstract] [Full Text] [Related]

  • 12. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.
    Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL.
    Clin Cancer Res; 2003 Jan 01; 9(1):295-306. PubMed ID: 12538482
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis.
    Singh AS, Macpherson GR, Price DK, Schimel D, Figg WD.
    Oncol Rep; 2006 Mar 01; 15(3):519-24. PubMed ID: 16465406
    [Abstract] [Full Text] [Related]

  • 14. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
    Miwa S, Mizokami A, Keller ET, Taichman R, Zhang J, Namiki M.
    Cancer Res; 2005 Oct 01; 65(19):8818-25. PubMed ID: 16204052
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K, Mizokami A, Li YQ, Narimoto K, Sugimoto K, Kadono Y, Kitagawa Y, Konaka H, Koh E, Keller ET, Namiki M.
    Prostate; 2009 Aug 01; 69(11):1222-34. PubMed ID: 19434660
    [Abstract] [Full Text] [Related]

  • 17. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.
    Montague R, Hart CA, George NJ, Ramani VA, Brown MD, Clarke NW.
    Eur Urol; 2004 Sep 01; 46(3):389-401; discussion 401-2. PubMed ID: 15306113
    [Abstract] [Full Text] [Related]

  • 18. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
    Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ.
    Bone; 2008 May 01; 42(5):848-60. PubMed ID: 18325866
    [Abstract] [Full Text] [Related]

  • 19. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
    Kubo T, Shimose S, Matsuo T, Tanaka K, Yasunaga Y, Sakai A, Ochi M.
    J Orthop Res; 2006 Jun 01; 24(6):1138-44. PubMed ID: 16705696
    [Abstract] [Full Text] [Related]

  • 20. Zoledronic acid induces autophagic cell death in human prostate cancer cells.
    Lin JF, Lin YC, Lin YH, Tsai TF, Chou KY, Chen HE, Hwang TI.
    J Urol; 2011 Apr 01; 185(4):1490-6. PubMed ID: 21334668
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.